NCT07016763View on ClinicalTrials.gov

Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Allergic Rhinitis
Interventions
DIETARY_SUPPLEMENT

Oral fatty acid

Intervention therapy (treatment group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) and oral supplementation of FAs (550 mg/tablet), vitamin B6 (0.21 mg/tablet), perilla frutescens (20 mg/tablet) and liquorice (200/mg/tablet) (2 tablets a day with meals)

DRUG

Mometasone Furoate Nasal Spray (MFNS)

Standard therapy (control group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) only

Trial Locations (1)

00186

Isola Tiberina Hospital, Rome

All Listed Sponsors
lead

Isola Tiberina - Gemelli Isola Hospital, Rome, Italy

OTHER

NCT07016763 - Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis | Biotech Hunter | Biotech Hunter